Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors are applauding the pharmacy retailer's plan to close many of its unprofitable stores.

Why Walgreens Boots Alliance Stock Is Skyrocketing Today

Walgreens will close 1,200 stores over the next three years after announcing fourth-quarter earnings on Tuesday that beat analyst expectations, as the pharmacy chain—which reported future “significant” store closures earlier this year—works to free up its cash flow.

Walgreens Closing 1,200 Stores As Earnings Beat Projections

Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A) was one of the top risers on the S&P 500, jumping 10.4% as it announced plans to close most of its underperforming stores.  Investors were impressed by news that the drug store chain plans to close around 1,200 of its 8,700 US drugstores over the next three years, saying a quarter of its outlets are unprofitable.

Walgreen Boots Alliance plans to close 1,200 stores as annual losses double

While the top- and bottom-line numbers for Walgreens (WBA) give a sense of how the business performed in the quarter ended August 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Walgreens (WBA) Q4 Earnings: A Look at Key Metrics

Pharmacy chain operator has been hit by sluggish consumer spending and low drug reimbursement rates

Walgreens to shut 1,200 US stores with stock trading near 30-year lows

Walgreens Boots Alliance (WBA) said Tuesday that it is shutting around 1,200 stores over the next three years, as the drugstore chain moves to turn around its troubled U.S. business.

Walgreens Plans To Close 1,200 Stores Over Next Three Years

Walgreens Boots Alliance has announced plans to shutter 1,200 stores across the US over the next three years as the company embarks on a comprehensive turnaround strategy under new CEO Tim Wentworth.

Walgreens to close 1,200 stores as CEO Wentworth drives turnaround strategy

Walgreens Boots Alliance (WBA) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.67 per share a year ago.

Walgreens Boots Alliance (WBA) Surpasses Q4 Earnings and Revenue Estimates

Walgreens announced that it will close about 1,200 stores over the next three years, with 500 shuttering as early as next year. It's part of the company's turnaround effort.

Walgreens to close 1,200 stores as part of turnaround effort

Walgreens announced that it will shutter 1,200 stores over the next three years — and 500 locations in 2025 alone — as the drugstore giant seeks to slash $1 billion in costs.

Walgreens to close 1,200 stores nationwide, says 1 in 4 locations are unprofitable

Walgreens' stock has been hammered this year as consumer shopping patterns have changed, but the company's latest earnings are getting better reception.

Walgreens plans to close 1,200 stores as it looks for a turnaround

Walgreens topped Q4 estimates and announced plans to close 1,200 drug store locations, including 500 in fiscal 2025. Shares jumped.

Walgreens Stock Jumps As Ailing Drug Store Giant Plans To Cut 1,200 Locations

Walgreens to close about 1,200 stores in the US over the next three years. The closures follow a June announcement to shut 25% of its US locations.

Walgreens is closing 1,200 stores

Walgreens reported fiscal fourth-quarter sales and profit that beat Wall Street's expectations, reflecting the company's efforts to slash costs. The retail drugstore chain also said it plans to close roughly 1,200 stores over the next three years, which includes 500 closures in fiscal 2025 alone.

Walgreens says it will close 1,200 stores by 2027, as earnings top estimates

On a day when Walgreens Boots Alliance reported another $3 billion in losses, the drugstore chain said it will close 1,200 stores over three years in an effort to return to profitability and long-term growth.

Walgreens Loses Another $3 Billion And Plans To Close 1,200 Stores

Walgreens Boots Alliance said on Tuesday it would shut 1,200 stores over the next three years as new CEO Tim Wentworth plots a turnaround at the struggling pharmacy chain operator hit by sluggish consumer spending and low drug reimbursement rates.

Walgreens to shutter 1,200 stores as CEO Wentworth seeks turnaround

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the fiscal year and fourth quarter that ended Aug. 31, 2024. “Our financial results in the fiscal fourth quarter and full year 2024 reflected our disciplined execution on cost management, working capital initiatives and capex reduction. In fiscal 2025, we are focusing on stabilizing the retail pharmacy by optimizing our footprint, controlling operating costs, improving cash flow,.

Walgreens Boots Alliance Reports Fiscal Year 2024 Earnings

Walgreens Boots Alliance, Inc. WBA will release earnings results for its fourth quarter, before the opening bell on Tuesday, Oct. 15.

Walgreens Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Can this pharmacy retailer overcome this latest threat?

Walgreens: A New Risk Just Emerged for the Stock

Ford Motor Company

Altria

Dividend stocks should be an investor's priority.

Should You Buy the 3 Highest Yielding S&P Stocks?

Walgreens (NASDAQ: WBA) is scheduled to report its fiscal Q4 2024 results on Tuesday, October 15 (Walgreens' fiscal ends in August). We expect the company to post mixed results, with revenue of $34.9 billion and earnings of $0.38 per share, compared to the consensus estimates of $35.7 billion and $0.36, respectively.

Walgreens Q4 Earnings Preview: Don't Catch The Falling Knife

Shares of Walgreens Boots Alliance Inc (NASDAQ:WBA) are up 0.8% to trade at $8.99 this afternoon, brushing off this morning's price-target cut to $11 from $13 at Deutsche Bank.

Walgreens Stock Desperately Needs a Post-Earnings Pop

Besides Wall Street's top -and-bottom-line estimates for Walgreens (WBA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended August 2024.

Unlocking Q4 Potential of Walgreens (WBA): Exploring Wall Street Estimates for Key Metrics

These stocks offer a lot of dividend income, but are they worth the risk?

Walgreens Boots Alliance vs. Altria Group: What's the Better Dividend Stock to Own?

Archer-Daniels-Midland Company

Amcor Plc

Franklin Resources

Chevron

Con Ed

Fastenal

Federal Realty Investment Trust

Genuine Parts

Hormel Foods

Johnson & Johnson

Kenvue

Medtronic

Realty Income Corp

PepsiCo

J. M. Smucker

Solventum Corporation

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

"Dividend Aristocrats... in the S&P500 Index… have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 67 Aristocrats, screened as of October 7, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 10.5%-20.13% topped-by Franklin & Target.

News for Walgreens Stock (WBA)